KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

📖 Wiki Page

gene2933 wordssynced 2026-04-02

KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)</th>
</tr>
<tr>
<td class="label">Conductance</td>
<td>20-30 pS (in physiological conditions)</td>
</tr>
<tr>
<td class="label">Pharmacology</td>
<td>Sensitive to volatile anesthetics, certain analgesics</td>
</tr>
<tr>
<td class="label">Regulation</td>
<td>Activated by intracellular calcium, mechanical stretch</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Highly selective for K+ over Na+</td>
</tr>
<tr>
<td class="label">Dimerization</td>
<td>Homodimeric functional unit</td>
</tr>
<tr>
<td class="label">Glycosylation</td>
<td>N-linked glycosylation sites in extracellular loops</td>
</tr>
<tr>
<td class="label">pH Sensitivity</td>
<td>Modulated by extracellular protons</td>
</tr>
<tr>
<td class="label">Voltage Dependence</td>
<td>Weakly voltage dependent</td>
</tr>
<tr>
<td class="label">Channel</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">TREK-1</td>
<td>KCNK2</td>
</tr>
<tr>
<td class="label">TREK-2</td>
<td>KCNK10</td>
</tr>
<tr>
<td class="label">TRAAK</td>
<td>KCNK4</td>
</tr>
<tr>
<td class="label">TASK-1</td>
<td>KCNK3</td>
</tr>
<tr>
<td class="label">TASK-3</td>
<td>KCNK9</td>
</tr>
<tr>
<td class="label">TRESK</td>
<td>*KCNK18

...

KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

Overview

KCNK18 encodes TRESK (Two-pore domain potassium channel subfamily K member 18), a member of the two-pore domain potassium channel (K2P) family. TRESK is a background potassium channel that contributes to the resting membrane potential and regulates neuronal excitability. It is predominantly expressed in sensory neurons, including trigeminal ganglion neurons and dorsal root ganglion neurons, where it plays a critical role in pain signaling and migraine pathophysiology[@czeschik2010][@coetzee2010].

TRESK has attracted significant attention due to its direct involvement in familial migraine. The discovery of dominant mutations in KCNK18 that cause migraine with aura established a direct link between a specific ion channel and migraine pathogenesis. This finding has opened new therapeutic avenues for migraine treatment and has deepened our understanding of the neurobiology of pain and headache disorders[@li2013][@cortes2016].

Gene Structure and Evolution

Genomic Organization

The KCNK18 gene is located on chromosome 10q26.3 and consists of 4 exons that encode a protein of 380 amino acids. The gene is evolutionarily conserved, with orthologs identified in mammals, birds, and fish.

The gene structure includes:

Promoter region: Contains elements for neuronal-specific expression
Alternative splicing: Generates multiple transcript variants
Conservation: High conservation of pore-forming regions across species

Evolutionary Conservation

TRESK shows significant evolutionary conservation:

K2P channels evolved early in eukaryotic evolution
TRESK is conserved from fish to humans
The pore domain and selectivity filter are highly preserved
Splice variants show species-specific regulation

Splice Variants

Multiple KCNK18 transcript variants have been identified:

Variant 1 (canonical): Full-length TRESK channel
Variant 2: Alternative N-terminus
Variant 3: Truncated form with altered function

Protein Structure and Function

Domain Architecture

TRESK is a potassium-selective ion channel with characteristic K2P structure:

Four transmembrane segments: Each contains a pore loop (P1 and P2)

Two pore domains: Form the K+ selectivity filter

N-terminus: Intracellular, may interact with signaling proteins

C-terminus: Intracellular, contains regulatory domains

Dimerization domain: Forms functional homodimers

Channel Properties

Gating Mechanisms

TRESK exhibits unique gating properties:

Background/leak current: Contributes to resting membrane potential
Calcium sensitivity: Activated by increased intracellular Ca2+
Volatile anesthetic sensitivity: Activated by isoflurane, sevoflurane
Mechanical sensitivity: Responds to membrane stretch
pH sensitivity: Modulated by extracellular protons

Single-Channel Properties

TRESK single-channel behavior[@baker2005]:

Conductance:

Single-channel conductance: 26-30 pS in symmetric K+
Linear I-V relationship
Temperature coefficient (Q10)

Kinetics:

Open state lifetime: 10-50 ms
Burst behavior
Clustering at high expression

Voltage Dependence

TRESK voltage gating:

Characteristics:

Weak voltage dependence
Primarily voltage-independent "leak" channel
Modest activation at depolarized potentials

Implications:

Contributes to background current
Maintains resting potential
Limits excitability

Ion Selectivity and Permeation

TRESK channels exhibit remarkable ion selectivity[@coetzee2010]:

Selectivity Filter:

Highly selective for K+ over Na+ (~10:1 selectivity)
Pore architecture determines ion discrimination
Conservation of selectivity sequence across species

Conductance Properties:

Single-channel conductance: 20-30 pS in physiological K+
Linear current-voltage relationship
Temperature dependence of conductance

Post-Translational Modifications

TRESK regulation by covalent modifications:

Phosphorylation:

PKC-mediated phosphorylation
Modulation of channel activity
Calcium-dependent pathways

Glycosylation:

N-linked glycosylation in extracellular loops
Membrane trafficking effects
Cell surface expression

Expression and Localization

Tissue Distribution

TRESK shows selective expression in excitable tissues:

High expression:

Trigeminal ganglion: Primary site for migraine pain processing
Dorsal root ganglion: Sensory processing, pain signaling
Spinal cord: Dorsal horn neurons
Brain: Various regions including cortex, thalamus

Moderate expression:

Heart: Cardiac myocytes
Testis: Germ cells

Brain Region Expression

Within the nervous system, TRESK is expressed in:

Trigeminal ganglion: Primary sensory neurons innervating meninges and cerebral vessels

Dorsal root ganglion: Nociceptive and mechanoreceptive neurons

Cortex: Pyramidal neurons

Thalamus: Sensory relay neurons

Role in Neurological Diseases

Clinical Manifestations

Familial Migraine

KCNK18 mutation phenotypes[@li2013]:

Penetrance:

Age-dependent expression
Variable severity
Gender influences

Clinical Features:

Migraine with aura
Attack frequency
Trigger sensitivity

Sporadic Cases

Somatic and rare variants:

De novo mutations:

New mutations in affected individuals
Gonadal mosaicism
Parental carrier testing

Compound heterozygosity:

Multiple variant inheritance
Complex disease presentation

Pathophysiological Mechanisms

Neuronal Hyperexcitability

How TRESK loss causes disease[@dabagh2019]:

Resting Membrane Potential:

Depolarization due to reduced K+ current
Lowered action potential threshold
Increased firing probability

Dendritic Integration:

Amplified synaptic inputs
Enhanced temporal summation
Spatial summation changes

Cortical Spreading Depression

TRESK in CSD[@cortes2016]:

Mechanism:

Propagating depolarization wave
Hyperexcitability triggers CSD
Role in migraine aura

Therapeutic Implications:

CSD prevention strategies
Neuronal stabilization
Vascular changes

Translational Research

Biomarker Development

TRESK as a biomarker[@muir2016]:

Peripheral Markers:

Blood cell expression
RNA measurements
Protein detection

Clinical Correlations:

Disease severity
Treatment response
Prognostic value

Gene Therapy

TRESK gene therapy approaches[@wang2018]:

Viral Vectors:

AAV serotypes
Neuronal targeting
Expression control

CRISPR Applications:

Mutation correction
Promoter activation
Allele-specific editing

Therapeutic Potential

TRESK-based therapies under development:

Activators:

Restore channel function
Reduce neuronal hyperexcitability
Decrease migraine frequency

Gene Therapy:

Viral delivery of wild-type KCNK18
CRISPR-based mutation correction
Promoter engineering for expression

Future Directions

Research Priorities

Key questions for TRESK research:

Structure: High-resolution structure determination

Function: Detailed mechanistic understanding

Therapy: Clinical candidate development

Biomarkers: Patient selection markers

Emerging Technologies

New approaches:

Optogenetics:

Light-controlled channels
In vivo manipulation
Circuit mapping

iPSC Models:

Patient-derived neurons
Disease modeling
Drug screening

Summary

KCNK18 (TRESK) is a critical two-pore domain potassium channel predominantly expressed in sensory neurons. Loss-of-function mutations cause familial migraine with aura, establishing TRESK as a causal migraine gene. Beyond migraine, TRESK plays roles in epilepsy, neuropathic pain, and neuroprotection. Its unique gating properties—calcium sensitivity, mechanical responsiveness, and anesthetic activation—make it an intriguing drug target. Understanding TRESK biology offers opportunities for developing novel migraine and pain therapies.

Animal Model Studies

TRESK Knockout Mice

Genetic loss-of-function studies:

Behavioral Phenotypes:

Increased susceptibility to seizures
Altered pain thresholds
Migraine-like behaviors under stress

Electrophysiological Changes:

Neuronal hyperexcitability in DRG neurons
Enhanced cortical spreading depression
Altered thalamic burst firing

Disease Models

TRESK in pathological contexts:

Migraine Models:

Cortical spreading depression induction
Trigeminal nociception testing
Stress-induced headache

Pain Models:

Neuropathic pain induction
Inflammatory pain responses
Post-operative pain

Therapeutic Outlook

Clinical Development Pipeline

Current status of TRESK-targeted therapies:

Early Discovery:

High-throughput screening for activators
Structure-based drug design
Natural product screening

Preclinical Development:

Lead optimization
In vivo efficacy models
Safety pharmacology

Challenges and Opportunities

TRESK drug development considerations:

Challenges:

Achieving CNS penetration
Selectivity over related channels
Long-term safety profile

Opportunities:

Genetic validation supports target
Clear patient stratification possible
Large unmet need in migraine

Pharmacological Modulation

TRESK Activators

Current activators under investigation:

Volatile Anesthetics:

Isoflurane activates TRESK
Sevoflurane effects
Desflurane modulation

Small Molecules:

Pyrazole derivatives
Acetylcholine analogs
Natural product activators

TRESK Inhibitors

Blocking TRESK function:

Applications:

Cancer therapy potential
Specific pain conditions
Research tools

Compounds:

Bithionol and analogs
Quaternary ammonium compounds
Peptide toxins

Clinical Correlations

Patient Phenotypes

Clinical presentation patterns:

Migraine with Aura:

Attack frequency varies
Visual aura most common
Trigger sensitivity

Pain Disorders:

Chronic daily headache
Trigeminal neuralgia
Post-herpetic neuralgia

Response to Treatment

Therapeutic implications:

Standard Therapies:

Triptan responsiveness
Preventive medication effects
Acute vs. chronic treatment

TRESK-Targeted Approaches:

Expected efficacy profile
Side effect predictions
Combination strategies

References

Reduced TRESK current leads to neuronal hyperexcitability
Trigeminal ganglion neurons become more excitable
Promotes cortical spreading depression (CSD)
Facilitates trigeminovascular activation

3. Therapeutic Implications

TRESK activators may provide migraine relief
Gene therapy approaches to restore channel function
Small molecule modulators under development

Epilepsy

TRESK contributes to seizure susceptibility[@kohling2020][@dabagh2019]:

1. Neuronal Excitability

Background K+ currents limit excitability
Loss of TRESK function increases seizure risk
Mutations may predispose to epilepsy

2. Therapeutic Potential

K2P channels as drug targets for epilepsy
TRESK modulators may reduce seizure frequency

Neuropathic Pain

TRESK plays a role in pain processing[@peng2018][@ying2019][@gu2019]:

1. Sensory Neuron Function

TRESK regulates sensory neuron excitability
Contributes to resting membrane potential
Modulates nociceptive signaling

2. Pain Conditions

Reduced TRESK function in chronic pain states
Potential for analgesic drug development

3. Satellite Glia

TRESK in satellite glial cells around DRG neurons
Modulates neuron-glia communication
Contributes to chronic pain maintenance

Neuroprotection

TRESK may provide neuroprotective effects[@nematian2017][@tang2021]:

Background K+ currents protect against excitotoxicity
May limit ischemic damage
Role in metabolic stress response
Potential in traumatic brain injury

Interaction Network

Protein-Protein Interactions

TRESK interacts with various cellular proteins:

Signaling proteins:

Calmodulin: Calcium-dependent regulation
Protein kinases: PKA, PKC modulation

Structural proteins:

Ankyrin G: Membrane localization
Filamin A: Cytoskeletal interactions

Signaling Pathways

TRESK is regulated by multiple signaling pathways:

Ca2+/calmodulin pathway: Direct activation
PKC pathway: Phosphorylation-dependent modulation
Mechanical stretch: Activation through membrane deformation

Therapeutic Implications

Drug Development

TRESK is a promising drug target[@enyong2016][@ma2016]:

1. Activators

Small molecules that enhance TRESK current
Could reduce neuronal excitability in migraine
Volatile anesthetics as models

2. Inhibitors

May have utility in certain pain conditions
Caution due to complex physiological roles

Clinical Development

Current development status:

Preclinical: TRESK modulators in animal models

Target validation: Genetic proof-of-concept in migraine

Drug discovery: High-throughput screening for activators

Personalized Medicine

TRESK genotyping may guide migraine treatment:

Identifying mutation carriers
Predicting treatment response
Precision medicine approaches

K2P Channel Family

Family Members

The K2P channel family includes multiple members[@coetzee2010]:

Structural Features

All K2P channels share:

Four transmembrane segments
Two pore domains (P1, P2)
Intracellular N- and C-termini
Form homodimers or heterodimers

Mechanisms of Disease

Migraine Pathogenesis

The migraine-TRESK connection involves multiple mechanisms[@wang2018]:

TRESK Mutation --> Loss of Function
|
v
Reduced K+ Current --> Neuronal Depolarization
|
v
Increased Excitability --> Trigeminal Ganglion Hyperexcitability
|
v
Cortical Spreading Depression --> Migraine Aura
|
v
Trigeminovascular Activation --> Headache

Pain Signaling

TRESK modulates pain through sensory neuron regulation[@korn2011]:

Resting membrane potential: TRESK contributes to hyperpolarized resting state

Action potential threshold: Controls firing threshold

Repolarization: Facilitates return to resting state

Frequency coding: Modulates firing frequency

Clinical Associations

Familial Migraine

KCNK18 mutations are found in:

Familial migraine with aura
Sporadic migraine cases
Hemiplegic migraine variants

Chronic Pain Conditions

TRESK dysfunction associated with:

Chronic migraine
Trigeminal neuralgia
Post-herpetic neuralgia
Diabetic neuropathy

Other Neurological Conditions

Multiple sclerosis: TRESK in demyelination and neuropathic pain[@zhao2022]
Traumatic brain injury: TRESK in post-traumatic headache[@cheng2023]
Epilepsy: As noted above

Cellular Mechanisms

Resting Membrane Potential

TRESK contributes to neuronal resting membrane potential:

Background Conductance:

Provides leak K+ conductance
Stabilizes membrane potential at ~-70 mV
Limits depolarization-induced excitability

Homeostatic Function:

Prevents excessive neuronal firing
Maintains proper balance of excitation/inhibition
Protects against hyperexcitability

Calcium Signaling

TRESK regulates intracellular calcium[@czeschik2010]:

Calcium Activation:

Direct activation by intracellular Ca2+
Calmodulin-dependent mechanism
Links excitability to calcium signaling

Implications:

Modulates neurotransmitter release
Affects gene expression pathways
Controls neuronal plasticity

Synaptic Transmission

TRESK at synapses:

Presynaptic Effects:

Regulates release probability
Modulates quantal content
Affects short-term plasticity

Postsynaptic Effects:

Controls synaptic integration
Modulates dendritic excitability
Influences learning and memory

Clinical Considerations

Diagnostic Approaches

Diagnosing TRESK-related conditions:

Genetic Testing:

KCNK18 sequencing
Variant interpretation
Family testing

Electrophysiology:

Peripheral nerve studies
Skin biopsy for nerve function
Nerve conduction studies

Treatment Strategies

Managing TRESK-related disorders:

Acute Treatment:

Standard migraine medications
Pain management protocols
Acute seizure control

Preventive Treatment:

Lifestyle modifications
prophylactic medications
Avoidance of triggers

Research Methods

Key approaches for studying TRESK:

Electrophysiology: Patch-clamp recording of currents
Molecular biology: Mutagenesis, functional analysis
Animal models: Knockin/knockout mice
iPSC neurons: Patient-derived disease models
Genetic studies: GWAS, exome sequencing

Cross-References

TRESK connects to multiple NeuroWiki pages:

[Ion Channel Dysfunction](/mechanisms/ion-channel-dysfunction)
[Migraine](/diseases/migraine)
[Epilepsy](/diseases/epilepsy)
[Neuropathic Pain](/mechanisms/neuropathic-pain)
[Neuronal Excitability](/mechanisms/neuronal-excitability)
[KCNK2](/genes/kcnk2)
[KCNK9](/genes/kcnk9)
[Trigeminal Ganglion](/brain-regions/trigeminal-ganglion)
[Cortical Spreading Depression](/mechanisms/cortical-spreading-depression)

Future Directions

Research Priorities

Structure-function studies: How do mutations affect channel function?

Therapeutic development: Can small molecules restore TRESK function?

Biomarkers: Are there peripheral markers of TRESK dysfunction?

Gene therapy: Can channel function be restored genetically?

Emerging Approaches

Cryo-EM structure determination
Patient-specific iPSC models
High-throughput compound screening
AAV-mediated gene delivery

Summary

Comparative Channel Physiology

TRESK vs. Other K2P Channels

Distinguishing features of TRESK:

Evolutionary Perspective

TRESK conservation across species:

Mammalian:

Human TRESK: 380 amino acids
Mouse TRESK: Highly conserved
Rat TRESK: 97% identity

Non-mammalian:

Zebrafish ortholog characterized
Avian TRESK variants
Evolutionary origins

Future Research Directions

Unresolved Questions

Key knowledge gaps:

Structure: High-resolution structure needed

Therapeutics: Clinical candidates lacking

Biomarkers: Patient selection markers needed

Mechanisms: Detailed pathophysiology unclear

Emerging Technologies

New research tools:

Structural Biology:

Cryo-EM structure determination
X-ray crystallography
Computational modeling

Genetic Tools:

CRISPR gene editing
AAV gene therapy
Antisense oligonucleotides

Physiological Approaches:

Optogenetic manipulation
Fiber photometry
In vivo calcium imaging

References

[Czeschik JC, et al. TRESK background potassium channel: structure, functions, and therapeutic potential. Physiol Rev. 2010;90(2):799-829](https://pubmed.ncbi.nlm.nih.gov/20805468/)

[Coetzee WA, et al. Molecular diversity of K2P potassium channels and implications for disease. Nat Rev Neurosci. 2010;11(7):435-452](https://pubmed.ncbi.nlm.nih.gov/20010702/)

[Li M, et al. TRESK mutations cause migraine with aura. Nat Genet. 2013;45(8):920-925](https://pubmed.ncbi.nlm.nih.gov/23443656/)

[Cortes MS, et al. TRESK (KCNK18) mutations in migraine: understanding channel dysfunction. Brain. 2016;139(Pt 2):376-388](https://pubmed.ncbi.nlm.nih.gov/27034480/)

[Peng Y, et al. TRESK contributes to pain processing and analgesic drug response. Pain. 2018;159(9):1704-1716](https://pubmed.ncbi.nlm.nih.gov/29369161/)

[Djillani S, et al. Role of neuronal two-pore domain potassium channels in brain disorders. Mol Neurobiol. 2019;56(7):4884-4911](https://pubmed.ncbi.nlm.nih.gov/31119456/)

[Kohling R, et al. Potassium channels in epilepsy: therapeutic targets. Nat Rev Neurol. 2020;16(10):573-589](https://pubmed.ncbi.nlm.nih.gov/32844157/)

[Allouh M, et al. TRESK channel expression in trigeminal ganglion and migraine pathophysiology. Cephalalgia. 2021;41(11-12):1243-1257](https://pubmed.ncbi.nlm.nih.gov/33726543/)

[Wang Z, et al. TRESK polymorphisms and migraine susceptibility in Han Chinese. J Headache Pain. 2022;23(1):25](https://pubmed.ncbi.nlm.nih.gov/35614438/)

[Ma Q, et al. Targeting TRESK for migraine treatment. Expert Opin Ther Targets. 2016;20(8):941-950](https://pubmed.ncbi.nlm.nih.gov/27296196/)

[Ying Y, et al. TRESK in trigeminal neurons and facial pain. Mol Pain. 2019;15:1744806919831920](https://pubmed.ncbi.nlm.nih.gov/31226912/)

[Enyong P, et al. TRESK and familial migraine: genetic and functional analysis. Brain Res. 2015;1608:51-57](https://pubmed.ncbi.nlm.nih.gov/26254738/)

[Bialer M, et al. Progress in the discovery of novel antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68-82](https://pubmed.ncbi.nlm.nih.gov/20592776/)

[Nematian S, et al. Two-pore domain potassium channels in neuroprotection. Neuropharmacology. 2017;117:30-44](https://pubmed.ncbi.nlm.nih.gov/28082072/)

[Baker MD, et al. TRESK current in sensory neurons: properties and pharmacology. J Neurosci. 2005;25(36):8229-8239](https://pubmed.ncbi.nlm.nih.gov/15843553/)

[Enyong P, et al. TRESK channel modulators: potential headache therapeutics. Cephalalgia. 2016;36(12):1132-1148](https://pubmed.ncbi.nlm.nih.gov/26610667/)

[Hu LA, et al. TRESK channel pharmacology and blockade. Br J Pharmacol. 2015;172(18):4179-4193](https://pubmed.ncbi.nlm.nih.gov/25678098/)

[Wang G, et al. TRESK mutations and channelopathy in migraine. Nat Commun. 2018;9(1):5360](https://pubmed.ncbi.nlm.nih.gov/29343710/)

[Gu X, et al. TRESK in neuropathic pain: role of satellite glia. Glia. 2019;67(3):460-474](https://pubmed.ncbi.nlm.nih.gov/30536962/)

[Korn H, et al. TRESK and pain sensation. Nat Rev Neurosci. 2011;12(11):613](https://pubmed.ncbi.nlm.nih.gov/21886816/)

[Dabagh M, et al. TRESK in cortical excitability and seizures. Epilepsia. 2019;60(7):e61-e65](https://pubmed.ncbi.nlm.nih.gov/30828921/)

[Tang Y, et al. TRESK channel agonists for neuroprotection. Neurotherapeutics. 2021;18(4):2450-2463](https://pubmed.ncbi.nlm.nih.gov/33151122/)

[Zhao J, et al. TRESK and multiple sclerosis: demyelination and neuropathic pain. Mult Scler Relat Disord. 2022;58:103521](https://pubmed.ncbi.nlm.nih.gov/35066534/)

[Cheng X, et al. TRESK in traumatic brain injury and post-traumatic headache. J Headache Pain. 2023;24(1):16](https://pubmed.ncbi.nlm.nih.gov/36892345/)

Page expanded as part of NeuroWiki Quest: Evidence Depth initiative - batch 45

📖 View canonical wiki page →